PT-141 is a melanocortin receptor agonist that acts on the brain, not blood flow.

The short version

PT-141 (bremelanotide) is a small lab-made peptide — a short chain of amino acids — that switches on melanocortin MC3R/MC4R receptors (brain switches that influence sexual desire, appetite, and skin pigment). It works in the brain, not on blood flow, which makes it different from the more familiar erection drugs. The US FDA approved it in June 2019, but for one use only: low sexual desire that causes real distress in premenopausal women. Every other use — in men, for erectile problems, after menopause — is off-label and rests on much thinner evidence. This page summarizes what the studies and the label actually report. It is not medical advice.

What the PT-141 record establishes

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide and melanocortin MC3R/MC4R receptor agonist (a molecule that switches those receptors on) studied for sexual desire and arousal. It is an analogue of alpha-MSH (alpha-melanocyte-stimulating hormone — a natural brain signaling peptide), and it acts centrally: in the hypothalamus and limbic system, not on the vascular smooth muscle that PDE-5 inhibitors target ^[1][6].

The approval is real and the approval is narrow. The FDA approved bremelanotide injection in June 2019 (NDA 210557) for acquired, generalized hypoactive sexual desire disorder (HSDD — persistent low sexual desire that causes marked personal distress) in premenopausal women, and for nothing else ^[6]. The pivotal evidence is the RECONNECT program — two identical Phase 3 randomized controlled trials in 1,267 premenopausal women, each a placebo-controlled test of the 1.75 mg subcutaneous as-needed dose ^[3].

The effect in that approved population is statistically real but clinically modest. Across the integrated trial data, desire on the FSFI (the standard questionnaire that scores sexual desire) rose by +0.35 versus placebo, and distress about low desire (FSDS-DAO item 13) fell by -0.33 versus placebo, both P<.001 ^[3]. The tolerability record is equally part of the story: nausea reached about 40% over long-term use and was the leading reason participants stopped ^[4]. This site keeps the efficacy and the side-effect record side by side. For the mechanism in full, see how PT-141 works; for the safety detail, see tolerability and adverse events.

PT-141 Peptide: A Synthetic Melanocortin Analogue

The PT-141 peptide is a seven-amino-acid cyclic compound — molecular weight about 1,025 Da, formula C50H68N14O10, CAS 189691-06-3 — built as a cyclic lactam analogue of the natural hormone alpha-MSH ^[6]. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH; the ring (a lactam bridge between the Asp and Lys side chains) is what gives the molecule its stability advantage over linear melanocortin peptides.

Structurally it is closely related to the melanocortin agonist melanotan II, but with the C-terminal amide replaced by a carboxylic acid. The international nonproprietary name (INN) is bremelanotide; PT-141 is the laboratory designation for the same molecule. Material sold as 'PT-141 research chemical' is a laboratory material that sits outside the pharmaceutical approval framework, with no regulatory oversight of its identity, purity, or concentration — it is not the approved finished drug product ^[6].

How Does PT-141 Work?

PT-141 works by activating central melanocortin receptors — chiefly MC4R (the melanocortin 4 receptor), with secondary MC3R activity — that are concentrated in the brain rather than the bloodstream ^[1]. By stimulating MC4R in hypothalamic circuits such as the medial preoptic area, it is thought to engage dopaminergic pathways governing sexual motivation ^[9]. In rats and nonhuman primates, systemic administration produced erections and activated hypothalamic neurons (raised c-Fos, a marker of neuronal firing), consistent with a central rather than peripheral mechanism ^[1].

This is the single most misunderstood fact about the compound. Unlike PDE-5 inhibitors, which act on penile vascular smooth muscle to improve blood flow, PT-141 acts on the neural circuitry of desire. A randomized fMRI study in women with HSDD found that MC4R agonism altered how the brain processed erotic stimuli ^[5]. PT-141 does not act through the hypothalamic-pituitary-gonadal axis and does not raise testosterone. The central melanocortin mechanism is covered in full on its own page.

PT-141 for Women: The Approved HSDD Indication

PT-141 for women is the only FDA-approved use of the compound. Bremelanotide is approved for acquired, generalized HSDD in premenopausal women — meaning the low desire developed after a period of normal function, is not situation-specific, and causes real personal distress ^[6]. The two RECONNECT Phase 3 trials (n=1,267) met both coprimary endpoints: a statistically significant rise in FSFI desire (+0.35 integrated) and a statistically significant drop in desire-related distress (FSDS-DAO item 13, -0.33 integrated), each versus placebo over 24 weeks ^[3].

In the 52-week open-label extension (684 women), the desire improvements were sustained and no new safety signals emerged ^[4]. The effect sizes are honest to report as modest, and the trials' clinical meaningfulness has been debated in the literature ^[3][4]. The mechanistic basis traces back to female-rat work, where the melanocortin agonist selectively increased appetitive (solicitational) sexual behavior — proceptive, desire-driven behavior — without affecting reflexive responses or general activity ^[2].

PT-141 for Men: Off-Label and Investigational Erectile Research

PT-141 for men is off-label and investigational — it is not an approved use, and the evidence is early-phase, not established ^[6]. The approval covers premenopausal women with HSDD only; use in men, for erectile dysfunction, or in postmenopausal women falls outside it ^[6]. The early human signal came from dose-ranging work in men, where systemic bremelanotide produced rapid, dose-dependent erectile activity ^[1]. Early intranasal development in men with erectile dysfunction reported a statistically significant response above roughly 7 mg, but that route was later discontinued for pharmacokinetic variability.

The male/erectile literature should be read as preliminary. A 2023 Expression of Concern was issued for a 2008 bremelanotide erectile-dysfunction salvage study, so its findings are formally disputed and should not be treated as confirmatory ^[6]. No Phase 3 program supports an erectile indication. This digest reports the male data as investigational research, never as an approved or established use.

PT-141 Benefits in the Clinical Evidence

The documented PT-141 benefits in the clinical evidence are confined to the approved population and are modest in size. In premenopausal women with HSDD, bremelanotide increased sexual desire (FSFI desire +0.35 integrated, P<.001) and reduced the distress that low desire caused (FSDS-DAO item 13 -0.33 integrated, P<.001) versus placebo ^[3]. A distinguishing feature is that the action is spontaneous and central rather than blood-flow-dependent: an fMRI study found MC4R agonism raised self-reported desire for up to 24 hours and changed task-based brain processing of erotic cues ^[5].

No benefit outside HSDD in premenopausal women is FDA-supported. A separate research finding — reduced caloric intake and body weight at high-frequency dosing — reflects MC4R's role in appetite, not an approved therapeutic benefit ^[10]. Benefits and tolerability belong together: the documented PT-141 side effects record should be read before weighing any of this, and the label figure is set out under PT-141 dosage. This digest recommends no use to any reader.